公开(公告)号：MY169807A

公开(公告)日：2019-05-16

申请号：MYPI2011003724

申请日：2010-02-19

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  CHIU CHIEN-YU

Abstract: Cancer-targeting peptides and uses thereof in cancer therapy.

公开(公告)号：AU2016249991A1

公开(公告)日：2017-10-12

申请号：AU2016249991

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：SG11201706342PA

公开(公告)日：2017-09-28

申请号：SG11201706342P

申请日：2016-01-27

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  TANG CHUNG-TAO

IPC: A61K39/12 ,  A61P31/14 ,  A61P37/04 ,  C07K14/08 ,  C07K14/18 ,  C07K16/10 ,  G01N33/53

Abstract: Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V 12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.

公开(公告)号：CA2937123A1

公开(公告)日：2015-07-23

申请号：CA2937123

申请日：2015-01-16

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIH-CHI ,  HSU TSUI-LING ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: A61K39/395 ,  G01N33/574

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

公开(公告)号：SG188324A1

公开(公告)日：2013-04-30

申请号：SG2013014832

申请日：2011-08-30

Applicant: ACADEMIA SINICA ,  LIANG CHI MING

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN

Abstract: Title: ANTI-C-MET ANTIBODY AND METHODS OF USE THEREOF Abstract:

公开(公告)号：ES2902032T3

公开(公告)日：2022-03-24

申请号：ES15878250

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSU TSUI-LING ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIH-CHI ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: C07K16/18 ,  A61P35/00 ,  C07K16/30 ,  C12P19/14

Abstract: Anticuerpo monoclonal humanizado aislado que se une específicamente a Neu5Acα2 → 3Galβ1 → 3GalNAcβ1 → 3Galα1 → 4Galβ1 → 4Glcβ1, en el que el anticuerpo comprende un VH que tiene la SEQ ID NO: 147 y un VL que tiene la SEQ ID NO: 148.

公开(公告)号：ES2901173T3

公开(公告)日：2022-03-21

申请号：ES16744256

申请日：2016-01-30

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  MA CHE ,  WU HAN-CHUNG

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30 ,  C12P19/14

Abstract: Anticuerpo monoclonal aislado o un fragmento de unión del mismo que se une a Neu5Acα2 → 3Galβ1 → 3GalNAcβ1 → 3Galα1 → 4Galβ1 → 4Glcβ1 (hexasacárido SSEA-4), en el que el anticuerpo monoclonal aislado o el fragmento de unión del mismo es un anticuerpo desfucosilado que comprende una glicoforma de Fc unida a la región de Fc, en la que dicha glicoforma tiene la fórmula: **(Ver fórmula)** Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2 en la que el anticuerpo comprende una VH que tiene la SEQ ID NO: 147 y una VL que tiene la SEQ ID NO: 148.

公开(公告)号：DK3245225T3

公开(公告)日：2021-10-18

申请号：DK15878250

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  LOU YI-WEI ,  LIN CHIH-WEI ,  WU CHUNG-YI ,  WU HAN-CHUNG ,  YEH SHIH-CHI ,  HSU TSUI-LING

IPC: C07K16/18 ,  A61P35/00 ,  C07K16/30 ,  C12P19/14

公开(公告)号：AU2016249991B2

公开(公告)日：2021-03-25

申请号：AU2016249991

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：SG11201707949XA

公开(公告)日：2017-10-30

申请号：SG11201707949X

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.